Osteoporosis Treatment and MRONJ Prevention Guidelines

1. MRONJ Risk Associated with Denosumab (Prolia)

Denosumab 60 mg subcutaneously every 6 months for osteoporosis carries a 0–1 % incidence of medication‑related osteonecrosis of the jaw (MRONJ), which is markedly lower than the 0.7–6.9 % incidence observed with higher cancer‑treatment doses. (American Society of Clinical Oncology) 1
The patient‑year‑adjusted MRONJ incidence rises with treatment duration: approximately 1.1 % in the first year, 3.7 % in the second year, and 4.6 % per year thereafter. (American Society of Clinical Oncology) 1
In three pivotal osteoporosis trials, no MRONJ cases occurred during the primary study periods; cases were only reported in extension phases after longer exposure. (American Medical Association) 2
Longer duration of denosumab therapy correlates directly with higher MRONJ risk. (American Society of Clinical Oncology) 1

The American College of Physicians strongly recommends oral bisphosphonates (alendronate or risedronate) as the first‑line pharmacologic option for postmenopausal osteoporosis. (Strong recommendation) 3
High‑certainty evidence shows that oral bisphosphonates reduce hip fractures by 6 per 1,000 treated patients, clinical vertebral fractures by 18 per 1,000, and any clinical fracture by 24 per 1,000 over a 3‑year period. (High‑certainty) 3
Oral bisphosphonates have a lower MRONJ risk than denosumab, with an incidence of 0.01 %–0.06 % (1–6 cases per 10,000 patients) at standard osteoporosis dosing. (American Medical Association) 2
Preferred oral agents are alendronate 70 mg once weekly or risedronate 35 mg once weekly. (American College of Physicians) 3
Zoledronic acid 5 mg intravenously once yearly is an alternative for patients unable to tolerate oral agents, but requires renal function monitoring. (American Medical Association; American College of Physicians) [2][3]
Standard treatment duration for oral bisphosphonates is 5 years, after which a drug holiday may be considered for patients at lower fracture risk. (American College of Physicians) 3

Denosumab should be reserved for patients who have contraindications to, or experience adverse effects from, oral bisphosphonates. (American College of Physicians) 3

A comprehensive dental examination—including panoramic radiography—must be completed within 2 weeks of referral before initiating any bone‑modifying agent. (American Society of Clinical Oncology) 4
All necessary dental extractions and periodontal treatments should be performed prior to starting therapy. (American Society of Clinical Oncology) 4
Ill‑fitting dentures should be adjusted and sources of mucosal trauma eliminated before treatment. (American Society of Clinical Oncology) 4
Patients should receive education on lifelong oral hygiene and be scheduled for dental follow‑up every 6 months, with annual panoramic radiography. (American Society of Clinical Oncology) 4
During therapy, elective invasive dental procedures should be avoided when possible; if extraction is required, timing must be coordinated with the prescribing physician. (American Society of Clinical Oncology) 4
Rigorous oral hygiene and prompt, conservative management of any dental infections are essential throughout treatment. (American Society of Clinical Oncology) 4

Initiate oral bisphosphonate therapy (alendronate or risedronate) for a 5‑year course in newly diagnosed postmenopausal osteoporosis patients. (American College of Physicians) 3
After 5 years, reassess fracture risk; consider a drug holiday for patients with low‑risk features. (American College of Physicians) 3
Reserve denosumab for cases of bisphosphonate failure, intolerance, or contraindication, ensuring a complete dental work‑up beforehand. (American College of Physicians; American Society of Clinical Oncology) [3][4]
If denosumab is prescribed, maintain adequate calcium (≈1,000 mg/day) and vitamin D (≈800–2,000 IU/day) supplementation and establish a 6‑month dental follow‑up schedule. (American Society of Clinical Oncology) 4

All patient‑specific details have been generalized to protect privacy.

The American College of Rheumatology recommends denosumab as a second-line therapy for postmenopausal osteoporosis, with a 68% reduction in vertebral fractures, 40% reduction in hip fractures, and 20% reduction in nonvertebral fractures, in patients with a high fracture risk 5
Denosumab demonstrates superior fracture reduction in postmenopausal osteoporosis, with a significant reduction in vertebral, hip, and nonvertebral fractures, compared to placebo 5
Up to 70% of patients discontinue oral bisphosphonates in the first year due to gastrointestinal side effects, making denosumab a suitable alternative for patients with bisphosphonate intolerance 5

The American College of Rheumatology guidelines recommend oral bisphosphonates as first-line therapy, followed by denosumab when oral agents are not appropriate, with a strength of evidence level of 1 6, 7, 8, 9
Denosumab is specifically indicated for patients with bisphosphonate intolerance, with a high fracture risk, and a history of gastrointestinal contraindications or side effects with oral bisphosphonates 6, 7, 9

Pre-treatment oral examination is required to assess dental health and minimize the risk of osteonecrosis of the jaw (ONJ), with a risk of 0-1% with denosumab's osteoporosis dosing schedule 5
Calcium monitoring is essential, with a recommended daily intake of 1000-1200mg, to reduce the risk of hypocalcemia 6, 7
Vitamin D optimization is mandatory, with a recommended daily intake of 2000 IU, to reduce the risk of hypocalcemia and fractures 8

Renal function assessment is necessary to determine the risk of hypocalcemia and to adjust the denosumab dosing schedule if necessary 5
Provider must document plan for transition therapy if denosumab is discontinued, to prevent rapid bone loss and increased vertebral fracture risk 10